A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis

Shuntaro Saito 1, Katsuya Suzuki 1, Keiko Yoshimoto 1, Yuko Kaneko 1, Yoshihiro Matsumoto 2, Kunihiro Yamaoka 1 and Tsutomu Takeuchi 1*

Abstract

Background: Interleukin-6 (IL-6) transduces signals via phosphorylation of STAT3 (pSTAT3). Tocilizumab (TCZ) is an IL-6 receptor blocker, which, when administered intravenously every 4 weeks, efficiently ameliorates rheumatoid arthritis (RA). Since IL-6 signal strength varies among patients with RA, the intensity necessary for appropriate IL-6 signal inhibition by TCZ might vary between individuals. In a previous study, we have examined the clinical utility of increasing (dosing interval shortened to 3 weeks) and decreasing (interval extended to 5 weeks) the dose frequency of TCZ. However, there is currently no established method for accurately measuring the strength of IL-6 signal inhibition by TCZ among individual patients. We therefore sought to develop such an assay.

Methods: Whole blood samples were collected from RA patients with low disease activity (clinical disease activity index (CDAI) ≤ 10) who were treated with TCZ at dosing intervals of 3 weeks (3-week group, n = 10), 4 weeks (4-week group, n = 10) or 5 weeks (5-week group, n = 10), or with methotrexate (control group, n = 10). Recombinant human IL-6 (0, 0.1, 1, 10, 100 ng/ml) was exogenously added to whole blood and the proportion of pSTAT3-positive CD4+ T cells (%pSTAT3+/CD4+) was measured by Phosflow cytometric analysis.

Results: The addition of exogenous IL-6 increased the proportion of pSTAT3-positive CD4+ T cells in a dose-dependent manner in each group. Inhibition of IL-6 signaling was strongest in the 3-week dosing group, followed by the 4-week, 5-week and control group. Significant differences in %pSTAT3+/CD4+ cells were observed between dose interval groups when stimulated with 10 ng/ml and 100 ng/ml of IL-6.

Conclusion: Assessment of the proportion of pSTAT3-positive CD4+ T cells under IL-6 stimulation is a highly sensitive and useful method for determining differences in the strength of IL-6 signal inhibition in patients treated with TCZ. It is suggested that different TCZ treatment intervals were necessary to lower disease activity in each group of patients, and these findings also indicate that the IL-6 signaling pathway may differ in each RA patient. Our assay may support strategies for optimizing TCZ treatment in RA patients.

Keywords: Rheumatoid arthritis, Tocilizumab, Interleukin-6, Phosphorylated STAT3, CD4+ T cell

* Correspondence: tsutake@z5.keio.jp
1 Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjyuku-ku, Tokyo 160-8582, Japan
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Interleukin-6 (IL-6) is an inflammatory cytokine with an important role in the pathogenesis of rheumatoid arthritis (RA) [1]. When IL-6 binds to the membrane and soluble forms of the IL-6 receptor (mIL-6R and sIL-6R, respectively), each complex binds to glycoprotein (gp) 130 and induces the phosphorylation of Janus kinase (JAK), which leads to the subsequent phosphorylation of signal transducer and activator of transcription 3 (STAT3) [2]. Phosphorylation of the STAT3 tyrosine residue at position 705 (pY705) is essential for dimerization and nuclear translocation [3].

Tocilizumab (TCZ) is a humanized anti-IL-6 receptor monoclonal antibody that blocks IL-6 signal transduction by binding to mIL-6R and sIL-6R, and efficiently ameliorates RA disease activity at a standard intravenous dose of 8 mg/kg every 4 weeks [4, 5]. Since levels of IL-6 and sIL-6R in serum and synovial fluid vary significantly, IL-6 signal strength varies among patients with RA [6]. Therefore, the intensity necessary for appropriate IL-6 signal inhibition by TCZ might vary between individuals. We previously examined the clinical effect of increasing (dosing interval shortened to 3 weeks) and decreasing (interval extended to 5 weeks) the dose frequency of TCZ to confirm this hypothesis [7]. However, there was no established assay for assessing the strength of IL-6 signal inhibition by TCZ. Such an assay could help to optimize dose frequency and interpret the pharmacokinetics/pharmacodynamics of TCZ. Here, we report the development of an assay for assessing the strength of IL-6 signal inhibition and analysis of the factors associated with IL-6 signaling in RA patients who were treated with TCZ.

Methods
Patients
Whole blood samples were collected from a total of 40 patients with RA who met the 1987 American College of Rheumatology (ACR) and/or 2010 ACR/European League Against Rheumatism (EULAR) classification criteria [8, 9] and who had achieved low disease activity (defined by clinical disease activity index (CDAI) [10] ≤ 10) with treatment. Patients were treated with TCZ at dosing intervals of 3 weeks (3-week group, n = 10), 4 weeks (4-week group, n = 10) or 5 weeks (5-week group, n = 10), and those with methotrexate (control group, n = 10). Among TCZ-treated patients, TCZ had been administered more than three times in the same interval before blood sample collection.

This study was approved by the ethics committee of our institution (Ethics committee of Keio University School of Medicine, approval number: 20100080 and 20140488, Institutional Review Board of Chugai Pharmaceutical Co., Ltd.). Written informed consent was obtained from all patients. Dosing adjustment of TCZ was performed by the attending physicians with patient consent. The investigation was conducted according to the principles of the Declaration of Helsinki.

Collection of clinical data
Clinical information was collected from the patients’ medical records, including background characteristics and RA disease activity, methotrexate dose, serum levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), clinical disease activity index (CDAI) [10] and the health assessment questionnaire disability index (HAQ-DI). Clinical and laboratory assessments were performed on the days corresponding to TCZ administration.

Detection of intracellular pSTAT3
Whole blood samples were collected on the days of TCZ administration, before treatment. Blood samples were stimulated with different concentrations of recombinant human (rh) IL-6 (0, 0.1, 1, 10, 100 ng/ml). The proportion of phosphorylated STAT3 (pSTAT3)-positive cells was measured by phosflow cytometric analysis according to the manufacturer’s protocol (BD Phosflow, Franklin Lakes, NJ, USA). Briefly, whole blood cells from 100 μl of blood sample were stimulated with IL-6 for 15 minutes at 37 °C, and 1 ml of Lyse/Fix Buffer (BD Phosflow) was added for erythrocyte lysis and fixation of the phosphorylated status of STAT3. After fixation, cells were permeabilized with 1 ml of Perm buffer (BD Phosflow), then washed and stained for 60 minutes at room temperature in darkened conditions with the following fluorophore-labeled monoclonal antibodies: anti-CD3-PerCP-Cy5.5 (Biolegend, San Diego, CA, USA), anti-CD4-phycocerythrin (PE)-Cy7 (BD Pharmingen, Franklin Lakes, NJ, USA), anti-pSTAT3 (pY705)-AF488 (BD Phosflow), and anti-mouse immunoglobulin G isotype-matched controls (all from BD Biosciences). Stained cells were washed once with 3 ml of Wash Buffer (BD Phosflow) and analyzed by flow cytometry (MACSQuant Analyzer; Miltenyi Biotec, Bergisch Gladbach, Germany). We also performed analysis of the proportion of pSTAT3-positive CD4+ T cells in healthy individuals (n = 2).

Detection of cell surface expression of mIL-6R and gp130
The surface expression of mIL-6R and gp130 on CD4+ T cells from 50 μl of fresh whole blood was analyzed by flow cytometry on the same day as pSTAT3 detection by phosflow cytometric analysis; this was assessed in a proportion of patients in each group (3-week group, n = 5; 4-week group, n = 7; 5-week group, n = 5; control group, n = 8). Expression of mIL-6R and gp130 was assessed by examining the mean fluorescence intensity (MFI) of each molecule. Whole blood cells were stained for 30 minutes at room temperature in darkened conditions with the following fluorophore-labeled...
monoclonal antibodies: anti-CD3-Vioblue (BD Bioscience), anti-CD4-Viogreen (Miltenyi Biotec), anti-CD126 (mIL-6R)-phycoerythrin (PE, Biolegend), anti-CD130 (gp130)-FITC (Abcam, Cambridge, UK), and anti-mouse immunoglobulin G isotype-matched controls (VioGreen from Miltenyi Biotec, all others from BD Biosciences). Stained cells were washed twice with 2 ml of phosphate-buffered saline and analyzed on a MACSQuant Analyzer (Miltenyi Biotec).

Measurement of serum IL-6, sIL-6R and TCZ concentrations
The concentrations of IL-6 and sIL-6R in serum were measured by an ultra-sensitive kit (K-15007C-1, MSD, Gaithersburg, MD, USA) and an enzyme-linked immunosorbent assay (ELISA) kit (K151ALC-1, MSD), respectively, according to the manufacturers’ protocol. In order to decrease the interference of rheumatoid factor to ELISA measurement system, we added 200 μg of Immunoglobulin Inhibiting Reagent (6LD1074, Funakoshi Co., Ltd., Tokyo, Japan) to 60 μL of serum sample before the addition of detection antibody. Effective suppression of interference of rheumatoid factor with the addition of this reagent was shown in the report [11]. Serum TCZ levels were measured by a clinical laboratory testing company (SRL Inc., Tokyo, Japan).

Statistical analysis
Descriptive values are expressed as mean ± standard deviation (SD). Three or more groups were compared using the ruskal–Wallis test and chi-square test. Comparisons between two groups were conducted using the Wilcoxon test and Fisher’s exact test. Correlations were analyzed by Spearman’s correlation coefficient. P values <0.05 were regarded as significant. All statistical analyses were performed with JMP software 11.2.0 (SAS Institute, Cary, NC, USA).

Results
Patient characteristics
The characteristics of the four groups at the time of blood sample collection are summarized in Table 1. While no significant differences were found in sex, age, RA disease duration, positivity for rheumatoid factor or anti-cyclic citrullinated peptide antibody, the duration of TCZ administration was longer in the 5-week group compared to the other groups. The levels of CRP and ESR were slightly but significantly higher in the control group. There was no statistically significant difference in CDAI between the four groups. The clinical course before blood sample collection in the TCZ-treated groups is summarized in Additional file 1: Figure S1.

Proportion of pSTAT3-positive CD4+ T cells
A representative figure showing the detection of pSTAT3-positive cells in whole blood from patients in each group is shown in Fig. 1a. Since CD4+ T cells were the most sensitive to IL-6 stimulation compared with CD3+ CD4− T cells and CD3− cells (Fig. 1a), we focused on the proportion of pSTAT3-positive CD4+ T cells in the assay. The proportion of pSTAT3-positive CD4+ T cells (%pSTAT3+/CD4+) increased with exogenous rhIL-6 stimulation in a dose-dependent manner in each treatment group (Fig. 2a). Although all patients had low disease activity, inhibition of IL-6 signaling was strongest

| Table 1 Characteristics of patients who were either administered tocilizumab at different intervals or methotrexate |
|---------------------------------------------------------------|
| Sex (female, n/total n, %)  | 3-Week group (n = 10) | 4-Week group (n = 10) | 5-Week group (n = 10) | Control group (n = 10) | P value |
|----------------------------|
| Age (years)                | 55.3 (14.8)         | 65.0 (9.9)          | 62.0 (10.6)         | 66.7 (11.0)         | 0.27   |
| RA duration (months)       | 101.5 (86.5)        | 68.5 (74.6)        | 116.5 (92.5)       | 81.9 (78.7)        | 0.35   |
| Tocilizumab duration (months) | 27.1 (20.7)      | 11.9 (9.2)         | 39.6 (12.1)        | -                   | <0.01* |
| RF positive (n, %)         | 7/10, 70%           | 9/10, 90%          | 9/10, 90%          | 5/10, 50%          | 0.12   |
| ACPA positive (n, %)       | 5/8, 63%            | 7/10, 70%          | 8/10, 80%          | 6/10, 60%          | 0.77   |
| MTX use (n, %)             | 4/10, 40%           | 6/10, 60%          | 4/10, 40%          | 10/10, 100%        | 0.03*  |
| MTX dose (mg/week)        | 7.5 (4.1)           | 8.3 (2.0)          | 4.4 (0.9)          | 9.0 (3.6)          | 0.07   |
| CRP (mg/dl)                | 0.01 (0.02)         | 0.01 (0.02)        | 0.03 (0.03)        | 0.13 (0.10)        | <0.01* |
| ESR (mm/h)                 | 6.0 (4.7)           | 6.6 (5.6)          | 12.3 (14.4)        | 22.2 (12.8)        | <0.01* |
| CDAI                      | 5.2 (1.3-8.1)      | 1.7 (0.1-7.9)      | 1.7 (0.1-5.8)      | 3.6 (0.2-6.3)      | 0.07   |
| HAQ-DI                     | 1.1 (0.8)           | 0.5 (0.6)          | 0.3 (0.5)          | 0.5 (0.5)          | 0.06   |

Values are expressed as mean ± standard deviation (SD) unless stated otherwise
RA rheumatoid arthritis, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide antibody, MTX methotrexate, CRP C-reactive protein, ESR erythrocyte sedimentation rate, CDAI clinical disease activity index, HAQ-DI health assessment questionnaire disability index

*P < 0.05
in the 3-week group, followed by the 4-week, 5-week and control group for every IL-6 concentration (Fig. 2a).

In the 3-week group, %pSTAT3+/CD4+ was 0 ± 0.0%, suggesting complete inhibition of IL-6 signaling, with IL-6 concentrations of 0 to 10 ng/ml. This increased to 3.1 ± 3.0% with 100 ng/ml of IL-6, indicating low signal transduction. Similarly, in the 4-week group, complete inhibition of IL-6 signaling was observed at IL-6 concentrations of 0 to 1 ng/ml, while low levels of IL-6 signal transduction (%pSTAT3+/CD4+ = 5.6 ± 4.4%) were observed with 10 ng/ml of IL-6. In the 5-week group, %pSTAT3+/CD4+ was 12.2 ± 13.7% with 0.1 ng/ml of IL-6, and reached 27.3 ± 28.1% with 1 ng/ml of IL-6, although there was wide variation in this group. In the control group, very low levels of IL-6 signal transduction (%pSTAT3+/CD4+ = 0.8 ± 1.3%) were observed without exogenous IL-6 stimulation (0 ng/ml), and %pSTAT3+/CD4+ reached 58.6 ± 12.8% with 0.1 ng/ml of IL-6.

Fig. 1 Assessment of the strength of interleukin-6/phosphorylated STAT3 (IL-6/pSTAT3) signal inhibition. a Representative intracellular staining pattern of pSTAT3 in CD3+ cells, CD3+CD4− T cells and CD3+CD4+ T cells by flow cytometry (IL-6 stimulation = 100 ng/ml). b Measurement of the proportion of pSTAT3-positive CD4+ T cells with exogenous IL-6 stimulation (0, 0.1, 1, 10, 100 ng/ml) in each group of patients administered either tocilizumab (TCZ) at different intervals or methotrexate (MTX). Open histograms represent isotype control antibody staining and filled plots represent anti-pSTAT3 antibody staining.
Notably, there were significant differences in %pSTAT3+/CD4+ between combinations of any two groups at 10 ng/ml and 100 ng/ml concentrations of IL-6 stimulation (Fig. 2a). In addition, there was no significant difference in the proportion of pSTAT3-positive CD4+ T cells between healthy individuals and RA control patients treated without anti-IL6-R. The proportion of pSTAT3-positive CD4+ T cells in healthy individuals were included in the range of mean ± 2 SD of the RA control group, and was significantly higher than that in the 5-week group, in all concentrations of IL-6 stimulation (data not shown).

Other factors associated with IL-6 signaling

**Surface mIL-6R and gp130 expression in CD4+ T cells**
Although the MFI of mIL-6R on CD4+ T cells from the TCZ-treated groups was higher than that from the control group ($p < 0.05$ for all comparisons), there was no significant difference between the 3-week, 4-week or 5-week groups (Fig. 2b). The MFI levels of gp130 on CD4+ T cells were comparable among all groups (Fig. 2c).

**Serum IL-6 and sIL-6R levels**
The concentration of serum IL-6 was significantly higher in the 3-week and 4-week groups compared to the 5-week group, but there was no significant difference among the control groups. The concentration of serum sIL-6R was lower in the TCZ-treated groups compared to the control group (Fig. 2d).

**Serum TCZ concentration**
The concentration of serum TCZ was significantly lower in the TCZ-treated groups compared to the control group (Fig. 2e).

**Correlation between serum TCZ concentration and pSTAT3+/CD4+ T cells**
The correlation coefficient between serum TCZ concentration and pSTAT3+/CD4+ T cells was analyzed using Spearman's correlation coefficient and was found to be significant ($r = -0.94$, $p < 0.001$) (Fig. 2f).

**Concentration of IL-6 stimulation**

![Concentration of IL-6 stimulation](image)

**Fig. 2** Difference in phosphorylated STAT3 (pSTAT3)+/CD4+ T cells (%) and other factors associated with interleukin-6 (IL-6) signaling in each group of patients administered tocilizumab (TCZ) at different intervals and in the control group. Comparison of pSTAT3+/CD4+ T cells (%) under IL-6 stimulation (0, 0.1, 1, 10, 100 ng/ml) (a), mean fluorescence intensity (MFI) of the membrane form of IL-6 receptor (mIL-6R) in CD4+ T cells (b), MFI of gp130 in CD4+ T cells (c), serum IL-6 concentration (d), serum soluble form of IL-6 receptor (sIL-6R) concentration (e) and serum TCZ concentration (f) in each treatment group. g Correlation between serum TCZ concentration and pSTAT3+/CD4+ T cells (%) (IL-6 stimulation = 100 ng/ml) in the TCZ-treated group ($n = 30$). Wilcoxon test was used for comparing the groups. Correlation was analyzed by Spearman's correlation coefficient. w = week
discussed), but there was no significant difference between the 3-week and 4-week groups ($p = 0.21$, Fig. 2d). The concentration of sIL-6R was higher in the TCZ-treated group than in the control group ($p < 0.05$ for all comparisons), but there was no significant difference between the 3-week, 4-week, or 5-week groups (Fig. 2e).

**Serum TCZ level**

The concentration of serum TCZ was significantly higher in the 3-week group compared to all other groups ($p < 0.05$ for all comparisons). While TCZ concentration in the 4-week and 5-week groups was significantly higher than that in the control group ($p < 0.05$ for all comparisons), there was no significant difference between the 4-week and 5-week groups ($p = 0.09$; Fig. 2f). There was strong and significant inverse correlation (Rho = $-0.94$, $p < 0.001$) between serum TCZ and %pSTAT3+/CD4+ (IL-6 stimulation = 100 ng/ml), with a notable difference detected at low TCZ concentrations (Fig. 2g).

**Discussion**

We demonstrated that assessing the proportion of pSTAT3-positive CD4+ T cells under IL-6 stimulation is a highly sensitive and useful method for determining the strength of IL-6 signal inhibition between groups of patients who were administered TCZ at different intervals and the MTX-treated control group. There was no significant difference in the serum IL-6 concentration between the 3-week and 4-week groups. Serum IL-6 concentrations had different dynamics compared with %pSTAT3+/CD4+ T cells, suggesting that the proportion of pSTAT3-positive CD4+ T cells was not directly affected by serum IL-6. Despite strong inverse correlation between serum TCZ concentration and %pSTAT3+/CD4+ T cells, there was no significant difference in serum TCZ concentration between the 4-week and 5-week groups. This suggests that the proportion of pSTAT3-positive CD4+ T cells may not be directly affected by free serum-TCZ. Instead, it may be correlated with the binding rate of TCZ to the IL-6 receptor; however, we could not measure the binding rate in this study. This novel pSTAT3-positive CD4+ T cell assay was more sensitive for assessing the strength of IL-6 signal inhibition compared to measuring serum TCZ concentrations. Although sIL-6 concentration and mIL-6R expression on CD4+ T cells were higher in the TCZ-treated group than in the control group, there was no significant difference between the TCZ-treated groups. We hypothesized that the mIL-6R expression on CD4+ T cells may have been induced by a positive feedback mechanism in response to IL-6 signal inhibition, and that these values plateaued in each group. In addition, increased sIL-6R concentration may have been affected by reduced clearance rate by TCZ binding. Interestingly, gp130 expression in CD4+ T cells was equivalent in all TCZ-treated groups and the control group, suggesting that gp130 expression on CD4+ T cells is not affected by inhibition of IL-6 signal.

Our study demonstrated that the strength of IL-6/ pSTAT3 inhibition differed depending on the interval of TCZ administration, which all resulted in low disease activity in each group of patients with RA. Therefore, it is suggested that different TCZ treatment intervals were necessary to lower disease activity in each group of patients. These findings also indicate that the IL-6 signaling pathway may differ in each patient with RA, further supporting the applicability of an assay for assessing pSTAT3-positive CD4+ T cells under IL-6 stimulation as a tool for adjusting the TCZ interval in patients with RA.

This is the first study to assess the dynamic status of molecules associated with IL-6 signaling with respect to the dose frequency of TCZ. Since the novel assay system utilized in this study uses whole blood that contains TCZ, detection of the proportion of pSTAT3-positive CD4+ T cells reflects the strength of IL-6 signal inhibition by TCZ in vivo, and it is a unique system for assessing patients with RA under TCZ treatment. In addition, it is possible that the assay for pSTAT3-positive CD4+ T cells may reflect the strength of IL-6 signal inhibition by TCZ in the articular environment; however, since there are few studies on the articular concentration of TCZ, further studies are required to confirm this. The advantage of this assay is its high sensitivity for detecting differences in the strength of IL-6 signal inhibition, which could be applicable to other receptor blockade therapies.

We should note some limitations of our study. First, we could not assess the binding rate of TCZ to mIL-6R and sIL-6R; therefore, we could not determine the most influential factor for pSTAT3-positive CD4+ T cells. Second, although the detection rate of anti-TCZ antibodies has previously been reported to be infrequent [12], future studies should examine this further. Third, the ELISA method we utilized could not discriminate free IL-6 from IL-6 bound to its receptor, sIL-6R, nor free sIL-6R from sIL-6R bound to IL-6 and/or anti-IL-6R antibody: the data on IL-6 and sIL-6R represented the total amounts of these factors.

Since the variation of %pSTAT3+/CD4+ T cells within each group of TCZ-treated patients was relatively large, the pharmacokinetics/pharmacodynamics of TCZ might differ among individuals. Therefore, measurement of the proportion of pSTAT3-positive CD4+ T cells under IL-6 stimulation might support strategies to optimize treatment in patients with RA treated with TCZ. Further
studies are required to establish the clinical usefulness of assessing the strength of IL-6 signal inhibition with this assay in patients who require TCZ dose frequency adjustments.

Conclusions
We developed a highly sensitive bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with RA. This bioassay system may support strategies for optimizing TCZ treatment in patients with RA.

Additional file

Additional file 1: Figure S1. Transition in CDAI for each group of patients administered TCZ at different intervals. Transition in CDAI for the 3-week group (A), 4-week group (B) and 5-week group (C). TCZ: tocilizumab, CDAI: clinical disease activity index. (TIF 1404 kb)

Abbreviations
CDAI: Clinical disease activity index; CRP: C-reactive protein; ELISA: Enzyme-linked immunosorbent assay; ESR: Erythrocyte sedimentation rate; gpl30: Glycoprotein 130; HAQ-DI: Health assessment questionnaire disability index; IL-6: Interleukin-6; JAK: Janus kinase; MFI: Mean fluorescence intensity; mIL-6R: Membrane IL-6 receptor; pSTAT3: Phosphorylated signal transducer and activator of transcription 3; RA: Rheumatoid arthritis; sIL-6R: Soluble IL-6 receptor; TCZ: Tocilizumab

Acknowledgements
We would like to thank Ms. Harumi Kondo and Ms. Mayumi Ohta for their assistance with collection of clinical data.

Funding
This study was funded by intramural research expense from Keio University School of Medicine and was financially supported in part by Chugai Pharmaceutical Co., Ltd.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
SS, KS, YK and TT participated in the study conception and design. AN, KS, Kyo, YK and TT participated in the acquisition of data, and analysis and interpretation of data. SS, KS and TT were involved in drafting the manuscript. All authors were involved in reviewing it critically for important intellectual content, and revising the final version. TT had full access to all data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved by the ethics committee of our institution (Ethics Committee of Keio University School of Medicine, approval number: 20100080 and 20140488, Institutional Review Board of Chugai Pharmaceutical Co., Ltd.). Written informed consent was obtained from all participants.

Consent for publication
Consent for publication was obtained from all participants.

Competing interests
SS has received speaking fees from Chugai Pharmaceutical, Eisai and Pfizer Japan. KS has received research grants from Eisai, Bristol-Myers Squibb, Kissei Pharmaceutical, Daiichi-Sankyo, and speaking fees from Abbvie Japan, Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Fuji Film Limited, Janssen Pharmaceutical, Kissei Pharmaceutical, Mitsubishi Tanabe Pharmaceutical, Pfizer Japan, Shionogi, Takeda Pharmaceutical, UCB Japan and consulting fees from Abbvie, Pfizer Japan. KYo has nothing declared. YK has received research grants or lecture fees from Abbvie, Eisai Pharmaceutical, Chugai Pharmaceutical, Bristol Myers Squibb, Astellas Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Pfizer, Janssen and UCB. YM is an employee of Chugai Pharmaceutical Co., Ltd. KYa has received consultant fees from Pfizer, Chugai Pharma, Mitsubishi-Tanabe Pharma, Abbvie, received honoraria from Pfizer, Chugai Pharma, Mitsubishi-Tanabe Pharma, Bristol-Myers Squibb, Takeda Industrial Pharma, GlaxoSmithKline, Nippon Shinyaku, Eli Lilly, Janssen Pharma, Eisai Pharma, Astellas Pharma, Actelion Pharmaceuticals and received research support from Chugai Pharma, Mitsubishi-Tanabe Pharma. TT has received research grants from Astellas Pharma Inc, Bristol–Myers KK, Chugai Pharmaceutical Co., Ltd, Daichii Sankyo Co., Ltd, Takeda Pharmaceutical Co., Ltd, Teijin Pharma Ltd, Abbvie GK, Ashahikasei Pharma Corp., Mitsubishi Tanabe Pharma Co, Pfizer Japan Inc., and Taisho Toyama Pharmaceutical Co., Ltd., Eisai Co., Ltd., AYUMI Pharmaceutical Corporation, and speaking fees from Abbvie GK, Bristol–Myers KK, Chugai Pharmaceutical Co., Ltd, Mitsubishi Tanabe Pharma Co, Pfizer Japan Inc, and Astellas Pharma Inc, and Daichi Sankyo Co., Ltd, and Consultant fees from Astra Zeneca KK, Eli Lilly Japan KK, Novartis Pharma KK, Mitsubishi Tanabe Pharma Co, Abbvie GK, Nipponkayaku Co., Ltd, Janssen Pharmaceutical KK, and Astellas Pharma Inc.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. 2Product Research Department, Chugai Pharmaceutical Co., Ltd, 1-1 Nihombashi-Muramachi 2-Chome, Chuou-ku, Tokyo 103-8324, Japan.

Received: 22 March 2017 Accepted: 20 September 2017

Published online: 17 October 2017

References
1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19.
2. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shinya M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2012;122(4):143–59.
3. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S, Sung B. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann NY Acad Sci. 2009;1171:59–76.
4. Dongolos M, Kisel K, Sheeren T, Tak PP, Conaghan PG, Mola EM, Schett G, Amital H, Navario-Sarabia F, Hou A, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72(1):43–50.
5. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Aganwal S, Green J, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541–50.
6. Houssiau FA, Devogelaer JP, Van Damme J, De Deuchains CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31(8):784–9.
7. Saito S, Kaneko Y, Izumi K, Takeuchi T. Utility of dose frequency adjustment in tocilizumab administration for rheumatoid arthritis. J Rheumatol. 2017;44(5):533–7.
8. Annett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(5):315–24.
9. Aletaha DA, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd CO, Bilmbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.

Note
Received: 22 March 2017 Accepted: 20 September 2017

Published online: 17 October 2017

Accepted: 20 September 2017

Published online: 17 October 2017

Accepted: 20 September 2017

Published online: 17 October 2017

Reference
10. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, van Riel PL, Tugwell P. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42(2):244–57.

11. Todd DJ, Knowlton N, Amato M, Frank MB, Schur PH, Izmailova ES, Rubenoff R, Shadick NA, Weinblatt ME, Centola M, et al. Erroneous augmentation of multiplex assay measurements in patients with rheumatoid arthritis due to heterophilic binding by serum rheumatoid factor. Arthritis Rheum. 2011;63(4):894–903.

12. Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, Hansen MS, Amital H, Xavier RM, Troum O, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014;73(5):803–9.